Skip to the lineages
Regenerative Medicine

What Is Stromal Vascular Fraction (SVF) From Adipose Tissue?

Published November 16, 2026

Protocol: 7 steps in this guide
  1. Fat tissue and the cells inside it
  2. What SVF contains
  3. Enzymatic versus mechanical processing
  4. SVF versus culture-expanded MSCs
  5. Product identity and contamination risks
  6. Clinical research versus regulatory status
  7. Questions to ask a seller

Stromal vascular fraction (SVF) is the mix of cells left when fat removed by liposuction is processed to break down the fat tissue and separate out its non-fat cells. It contains a variety of cell types, of which adipose-derived stromal cells are one part. It is not a single defined product: what it contains depends on how it is isolated. In FDA’s guidance, processing fat to isolate SVF is generally considered more than minimal manipulation, which matters for how such products are regulated. No SVF product is FDA-approved for a joint condition.

Fat tissue and the cells inside it

FDA’s 2020 guidance Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use describes adipose tissue as a connective tissue made of clusters of fat cells, called adipocytes, surrounded by a fiber network and small blood vessels. It notes that fat also contains “other cells, including preadipocytes, fibroblasts, vascular endothelial cells, and macrophages.” Because fat is mainly adipocytes and connective tissue that provide cushioning and support, FDA treats it as a structural tissue for regulatory purposes.

What SVF contains

SVF is the non-fat-cell portion. FDA’s guidance describes processing that isolates “cellular components” of fat, “commonly referred to as stromal vascular fraction, which is considered a potential source of adipose-derived stromal/stem cells.” A 2025 meta-analysis in Stem Cell Research & Therapy, Mechanical isolation of stromal vascular fraction from adipose tissue, reported pooled marker levels in mechanically isolated SVF of 4.08% for CD105 and 11.63% for CD73, markers associated with adipose-derived stromal cells, and 8.70% for CD34, which it attributes to “vascular and hematopoietic progenitor subpopulations commonly found in SVF.” These are single-marker percentages reported in that analysis. They do not by themselves give the share of stromal cells, which depends on which markers are found together on the same cells and on how the cells were counted, and fresh SVF cells can carry different markers from cells grown in culture. What they do show is that SVF is a mixed population.

Stage What is present
Fat tissue removed by liposuction Fat cells, connective tissue, blood vessels and other cells
After processing Depends on the method: a suspension of mixed cells, or with some mechanical methods small tissue fragments as well
SVF Several cell types, including a fraction of stromal cells
Culture-expanded adipose stromal cells A single cell type grown in a laboratory; a different product

Enzymatic versus mechanical processing

SVF can be isolated with enzymes that digest the tissue or with mechanical methods. A 2024 systematic review in Wound Repair and Regeneration, Comparing mechanical and enzymatic isolation procedures to isolate adipose-derived stromal vascular fraction, found that mechanical procedures took 8 to 20 minutes compared with 50 to 210 minutes for enzymatic ones, but concluded that because studies used poorly validated measures, “it still remains unclear which intraoperative SVF isolation method is preferred.” The same review distinguishes cellular SVF from tissue SVF, so products sold under the SVF name are not all the same.

The method does not, by itself, settle regulatory status. FDA’s guidance gives an example of fat recovered by liposuction and processed, “e.g., enzymatically digests, mechanically disrupts, etc.,” to isolate SVF, and states that in that example the product “generally is considered more than minimally manipulated because the processing breaks down and eliminates the adipocytes and the surrounding structural components.” The same guidance states that using an adipose-derived product to treat “a degenerative, inflammatory, or demyelinating disorder would generally be considered a non-homologous use.”

SVF versus culture-expanded MSCs

SVF is a mixed population produced in one session. Culture-expanded mesenchymal stromal cells are isolated and grown in a laboratory, which changes both the product and the questions about it. The laboratory criteria that define MSCs are covered in what mesenchymal stromal cells are. Calling SVF “stem cells” overstates what a mixed fraction contains.

Product identity and contamination risks

Because SVF composition varies with the method, a product is defined by its isolation system, its release testing and its dose, not by the label “SVF.” Cell-count and viability claims should come from testing of the product itself; how viability is measured is covered in what cell viability means for injectable cell products. SVF involves liposuction and processing as well as an injection. FDA’s patient and consumer information on regenerative medicine therapies names “stromal vascular fraction (fat-derived cells)” among unapproved products, “whether recovered from your own body or another person’s body,” and lists safety concerns with illegally marketed products that include bacterial infections and reactions at the site of collection and administration.

Clinical research versus regulatory status

SVF is being tested in regulated trials, which shows what a defined product looks like. A 2026 multicenter randomized placebo-controlled trial in the American Journal of Sports Medicine (Garza and colleagues) gave a single injection of 25 million autologous SVF cells, prepared during the same visit with a point-of-care isolation system and checked “against predefined release criteria,” to people with moderate-to-severe knee osteoarthritis. It was run under an FDA investigational device exemption (IDE 16734). CMS’s record for the approved IDE study BB16734-NCT04440189 lists it as a study of the “GID SVF-2 Device” with GID BIO, INC as sponsor; the device and the sponsor carry the same company name, which is relevant when weighing the results. Its results are reviewed in what clinical trials show about stem cell injections for knee osteoarthritis.

A trial under an investigational exemption is not approval; FDA’s patient notice, which names stromal vascular fraction among the unapproved products it warns about, states that these products “have not been approved for the treatment of any orthopedic condition.” The rules are covered in how the FDA regulates stem cell products promoted for joint pain.

Questions to ask a seller

  1. Is the procedure part of a registered study under an FDA IND or IDE? If so, what number?
  2. What isolation system is used, and is it the one tested in any published trial?
  3. Is the product tested before injection, and what are the release criteria?
  4. How many cells are injected, and how was that number measured?
  5. What are the risks of the liposuction step as well as the injection?

Stromal vascular fraction is a mixed population of non-fat cells isolated from liposuctioned fat, whose content varies with the processing method, and FDA’s guidance generally treats its isolation as more than minimal manipulation, so an SVF injection for a joint should be understood as an investigational product rather than an approved treatment.

Cells linked to this one

This guide leads on to

Guides that lead here

Lineage E: Stem Cell Sources and Products

1 reader remark

Add a remark

Your email address will not be published. Required fields are marked *